Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study

• Published in: Pituitary 2020-04, Vol.23 (2), p.171-181
• Main Authors: Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Caron, Philippe J.
• Format: Article
• Language: English
• Subjects: Acromegaly; Acromegaly - drug therapy; Acromegaly - metabolism; Adult; Body mass index; Endocrinology; Female; Growth hormone; Human Growth Hormone - blood; Human Physiology; Humans; Insulin; Insulin-like growth factor I; Insulin-Like Growth Factor I - metabolism; Insulin-like growth factors; Logistic Models; Male; Medical treatment; Medicine; Medicine & Public Health; Middle Aged; Peptides, Cyclic - therapeutic use; Pituitary; ROC Curve; Sex; Somatostatin; Somatostatin - analogs & derivatives; Somatostatin - therapeutic use
• ISSN: 1386-341X; 1573-7403
• DOI: 10.1007/s11102-019-01020-3

Purpose PRIMARYS (NCT00690898) was a 48-week, open-label, phase 3b study, evaluating treatment with the somatostatin receptor ligand lanreotide autogel (stable dose: 120 mg/28 days) in treatment-naïve patients with growth hormone (GH)-secreting pituitary macroadenoma. This post hoc analysis aimed to evaluate factors predictive of long-term responses. Methods Potential predictive factors evaluated were: sex, age, and body mass index at baseline; and GH, insulin-like growth factor-1 (IGF-1), and tumor volume (TV) at baseline and week 12, using univariate regression analyses. Treatment responses were defined as hormonal control (GH ≤ 2.5 µg/L and age- and sex-normalized IGF-1), tight hormonal control (GH